CD8A and neoplasm: The oligoclonal nature of CD8+ T cell responses against the CT26 tumor antigen AH1 in mice treated with immunotherapy (34) makes the CT26 model an excellent system in which to study the impact of a clinically significant variable, the duration of ATR inhibitor treatment, on tumor antigen–specific CD8+ T cell responses.